Christopher P. Scally
YOU?
Author Swipe
View article: Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous Neoplasms
Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous Neoplasms Open
Background Although 2016 consensus guidelines defined high-grade appendiceal mucinous neoplasms (HAMNs) as a distinct histologic entity, their clinical course and optimal management remain poorly characterized. Comparative data with low-gr…
View article: Hyalinization-based pathologic response and immune infiltration following neoadjuvant radiotherapy with or without immune-checkpoint blockade in localized undifferentiated pleomorphic sarcoma
Hyalinization-based pathologic response and immune infiltration following neoadjuvant radiotherapy with or without immune-checkpoint blockade in localized undifferentiated pleomorphic sarcoma Open
HPR was significantly associated with improved overall and recurrence-free survival, regardless of treatment, although use of ICB led to better outcomes. These findings support the need to explore the role of ICB with chemotherapy and RT t…
View article: Outcomes following diagnostic laparoscopy in patients with peritoneal carcinomatosis deemed ineligible for cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) due to disease burden
Outcomes following diagnostic laparoscopy in patients with peritoneal carcinomatosis deemed ineligible for cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) due to disease burden Open
View article: Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience
Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience Open
Background Dedifferentiated liposarcoma (DDLPS) is one of the most common types of soft tissue sarcoma (STS) characterized by liposarcomatous differentiation and a predilection for the retroperitoneum. Despite the growing number of histolo…
View article: Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis
Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis Open
View article: Optimal surveillance for detecting sarcoma lung metastasis – A systematic review
Optimal surveillance for detecting sarcoma lung metastasis – A systematic review Open
View article: Peritoneal Cancer Index Correlates with Radiographic Assessment of Colorectal Carcinomatosis
Peritoneal Cancer Index Correlates with Radiographic Assessment of Colorectal Carcinomatosis Open
View article: Plasma DNA Methylation‐Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1
Plasma DNA Methylation‐Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1 Open
Malignant peripheral nerve sheath tumor (MPNST) development is characterized by an altered DNA methylation landscape, which presents a promising area for developing MPNST‐specific biomarkers for screening patients with NF1. Genome‐wide DNA…
View article: Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma Open
Importance Serum tumor markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cancer antigen 125 (CA125) have been useful in the management of gastrointestinal and gynecological cancers; however, there is limited i…
View article: SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection
SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection Open
View article: Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit
Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit Open
Introduction Many patients with mucinous appendiceal adenocarcinoma experience peritoneal recurrence despite complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Prior work has demonstrated that repea…
View article: ASO Visual Abstract: Treatment Variation and Long-Term Outcomes of Low-Grade Appendiceal Neoplasms
ASO Visual Abstract: Treatment Variation and Long-Term Outcomes of Low-Grade Appendiceal Neoplasms Open
View article: The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma
The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma Open
Importance Serum tumor markers CEA, CA19-9, & CA125 have been useful in the management of gastrointestinal and gynecological cancers, however there is limited information regarding their utility in patients with appendiceal adenocarcinoma.…
View article: Neighborhood-Level Socioeconomic Disadvantage Predicts Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy
Neighborhood-Level Socioeconomic Disadvantage Predicts Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy Open
View article: Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma
Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma Open
Importance Appendiceal adenocarcinoma is a rare tumor, and given the inherent difficulties in performing prospective trials in such a rare disease, there are currently minimal high-quality data to guide treatment decisions, highlighting th…
View article: Supplementary Protocol from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Supplementary Protocol from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma Open
Study Protocol
View article: Supplementary Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Supplementary Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma Open
Supplementary Methods, Figures and Tables
View article: Supplementary Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Supplementary Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma Open
Supplementary Methods, Figures and Tables
View article: Supplementary Protocol from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Supplementary Protocol from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma Open
Study Protocol
View article: Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma Open
Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive malignancy with limited treatment options. VEGF inhibition enhances efficacy of immune-checkpoint inhibitors by reworking the immunosuppressive tumor milieu. Efficacy and sa…
View article: Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma Open
Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive malignancy with limited treatment options. VEGF inhibition enhances efficacy of immune-checkpoint inhibitors by reworking the immunosuppressive tumor milieu. Efficacy and sa…
View article: A Prospective Randomized Crossover Trial of Systemic Chemotherapy in Patients with Low-Grade Mucinous Appendiceal Adenocarcinoma
A Prospective Randomized Crossover Trial of Systemic Chemotherapy in Patients with Low-Grade Mucinous Appendiceal Adenocarcinoma Open
Importance Appendiceal Adenocarcinoma is a rare tumor and given the inherent difficulties in performing prospective trials in such a rare disease currently there is a scant amount of high-quality data upon which to guide treatment decision…
View article: Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial
Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial Open
View article: 618 Dietary fiber intake is associated with increased tertiary lymphoid structures in dedifferentiated liposarcoma following immune checkpoint blockade
618 Dietary fiber intake is associated with increased tertiary lymphoid structures in dedifferentiated liposarcoma following immune checkpoint blockade Open
Background Recent evidence suggests that dietary fiber intake is associated with improved clinical and pathologic response to anti-PD-1 therapy,1 though this relationship is unclear in soft-tissue sarcoma. We evaluated the impac…
View article: ASO Visual Abstract: Re-Excision After Unplanned Excision of Soft Tissue Sarcoma Is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease
ASO Visual Abstract: Re-Excision After Unplanned Excision of Soft Tissue Sarcoma Is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease Open
View article: The immune landscape of undifferentiated pleomorphic sarcoma
The immune landscape of undifferentiated pleomorphic sarcoma Open
Introduction Undifferentiated pleomorphic sarcoma (UPS) can be associated with a relatively dense immune infiltration. Immune checkpoint inhibitors (anti-PD1, anti-PDL1, and anti-CTLA4) are effective in 20% of UPS patients. We characterize…
View article: A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients
A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients Open
View article: Adoption of Telemedicine for Postoperative Follow-Up After Inpatient Cancer-Related Surgery
Adoption of Telemedicine for Postoperative Follow-Up After Inpatient Cancer-Related Surgery Open
PURPOSE: The COVID-19 pandemic has resulted in significant changes in health care delivery, including the rapid adoption of telemedicine across multiple specialties and practice environments. This includes postoperative visits (POV), despi…
View article: <scp>Real‐world</scp> use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center
<span>Real‐world</span> use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center Open
Palbociclib has been evaluated in early phase trials for well‐differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) patients, with reported median progression‐free survival (PFS) of 18 weeks. Here, we report on real‐w…
View article: A Prospective Randomized Crossover Trial of Systemic Chemotherapy in Patients with Low-Grade Mucinous Appendiceal Adenocarcinoma
A Prospective Randomized Crossover Trial of Systemic Chemotherapy in Patients with Low-Grade Mucinous Appendiceal Adenocarcinoma Open